Form 4: MIMEDX Director Todd Newton Receives Annual Restricted Stock Grant Valued at $6.47 Per Share

MIMEDX Group, Inc. Director Todd Newton was granted 28,609 shares of common stock as part of his annual restricted stock compensation, valued at $6.47 per share.

Summary

• Todd Newton, a Director of MIMEDX GROUP, INC. (MDXG), acquired 28,609 shares of common stock.
• The transaction date for this acquisition was June 18, 2025.
• The shares were acquired at a price of $6.47 per share.
• Following this transaction, Mr. Newton beneficially owns 412,771 shares of MIMEDX common stock.
• This acquisition represents an annual restricted stock grant to non-employee directors.
• The grant is exempt under SEC Rule 16b-3.
• The award is set to vest upon the earlier of 12 months from the grant date or the next annual meeting of shareholders.
• The transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 6

Explanation: The document reports a routine, expected insider transaction (an annual stock grant) which is generally neutral to slightly positive as it aligns insider interests with shareholders. It does not contain any negative or significantly positive news beyond this.

Positives

• The grant aligns the interests of Director Todd Newton with those of shareholders, as his compensation is tied to the company's equity performance.
• The transaction is a routine annual restricted stock grant, indicating a standard compensation practice for non-employee directors.

Future Outlook

The restricted stock grant is scheduled to vest upon the earlier of 12 months from the grant date or the next annual meeting of shareholders, indicating a future milestone for the shares to become fully owned.

Industry Context

This Form 4 filing details a standard compensation practice for a director of a publicly traded company in the healthcare/biotechnology sector, where equity grants are common for aligning executive and director interests with shareholder value.

Comparison to Industry Standards

• Annual restricted stock grants to non-employee directors are a common form of compensation across various industries, including healthcare and biotechnology, aligning director incentives with long-term company performance.
• The use of Rule 10b5-1(c) plans for such grants is standard practice to provide an affirmative defense against insider trading allegations for pre-planned transactions.

Related Party Transactions

• The restricted stock grant to Director Todd Newton can be considered a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant increases the number of outstanding shares, potentially leading to minor dilution, but also aligns the director's interests with shareholder value creation.
• Employees: No direct impact mentioned.

Next Steps

• The granted shares will vest upon the earlier of 12 months from the grant date or the next annual meeting of shareholders.

Key Dates

Recommendation

Keywords

MIMEDX GROUP, MDXG, Todd Newton, Director Compensation, Restricted Stock Grant, SEC Form 4, Insider Transaction, Equity Compensation, Rule 16b-3, Rule 10b5-1